OSLO,
Norway, Feb. 20, 2023 /PRNewswire/ -- Photocure
ASA, The Bladder Cancer Company, announces the presentation of
clinical data from the Veterans Affairs (VA) BRAVO study at the
ASCO Genitourinary Cancers Symposium (ASCO GU) which was held
February 16-18, 2023 in San Francisco, USA. The clinical data demonstrated a
significant decrease in the risk of recurrence & longer time to
recurrence following Blue Light cystoscopy (BLC®) with
Cysview® compared to White Light cystoscopy (WLC)
alone.
ASCO GU is a meeting of up to 5 000 healthcare professionals
focused on genitourinary cancers, offering the latest information
on scientific advances in the study, diagnosis and treatment of GU
malignancies. The program is known for being highly interactive
with multidisciplinary perspectives and attracts a global audience.
Presentations include the latest science and evidence-based
information on optimal patient care.
Dr. Steven Williams, University of Texas-Medical Branch, Galveston,
presented the study abstract "The Impact of Blue Light Cystoscopy
Use Among Non-Muscle Invasive Bladder Cancer Patients in an Equal
Access Setting: Implications on Recurrence and Time to Recurrence
Stratified by Race".
The study was conducted with support from Photocure and aims to
describe bladder cancer outcomes and the impact of blue light
cystoscopy (BLC®) with Cysview® among
non-muscle invasive bladder cancer (NMIBC) patients in an equal
access setting, i.e., the United States Veterans Affairs Healthcare
System (VA). Patients diagnosed with NMIBC within the VA who
received BLC were assessed to determine overall recurrence rates as
well as the association between race and recurrence, progression,
and overall survival outcomes.
A total of 378 patients were included in the analysis, of which
43 (11%) were African American and 300 (79%) were Caucasian. The
results showed that the median time to first recurrence following
BLC vs. WLC was significantly longer overall (40 vs. 26 months,
p<0.001) and across all time points, respectively, in the
cohort. A significant decrease in risk of recurrence following BLC
utilization compared to WLC alone was also determined (HR, 0.70,
p=0.005). With regard to race stratification, the analysis showed
no significant difference between African American and Caucasian
patients for recurrence, progression and overall
survival.
"Our findings demonstrate increased support for blue light
cystoscopy's clinical role in reducing bladder cancer recurrence,
and that equal access to health care can achieve equitable
outcomes. These data support current AUA/SUO guidelines
recommending BLC usage in patients with NMIBC to increase detection
and decrease recurrence." said Dr. Steven Williams, Professor and Chief of the
Division of Urology, at the University of
Texas-Medical Branch, and one of the study
authors.
*Read about the abstract:
https://meetings.asco.org/abstracts-presentations/216732
Note to editors
Hexvix®/Cysview® and BLC® are
registered trademarks of Photocure ASA.
This press release may contain product details and information
which are not valid, or a product that is not accessible, in your
country. Please be aware that Photocure does not take any
responsibility for accessing such information, which may not comply
with any legal process, regulation, registration, or usage in the
country of your origin.
About Bladder Cancer
Bladder cancer ranks as the 8th most common cancer worldwide –
the 5th most common in men – with 1 720 000 prevalent cases (5-year
prevalence rate)1a, 573 000 new cases and more than 200
000 deaths annually in 2020.1b
Approx. 75% of all bladder cancer cases occur in
men.1 It has a high recurrence rate, with up to 61% in
year one and up to 78% over five years.2 Bladder cancer
has the highest lifetime treatment costs per patient of all
cancers.3
Bladder cancer is a costly, potentially progressive disease for
which patients have to undergo multiple cystoscopies due to the
high risk of recurrence. There is an urgent need to improve both
the diagnosis and the management of bladder cancer for the benefit
of patients and healthcare systems alike.
Bladder cancer is classified into two types, non-muscle invasive
bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC),
depending on the depth of invasion in the bladder wall. NMIBC
remains in the inner layer of cells lining the bladder. These
cancers are the most common (75%) of all cases and include the
subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the
cancer has grown into deeper layers of the bladder wall. These
cancers, including subtypes T2, T3, and T4, are more likely to
spread and are harder to treat.4
1 Globocan. a) 5-year prevalence / b) incidence/mortality by
population. Available at: https://gco.iarc.fr/today, accessed
[January 2022].
2 Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
3 Sievert KD et al. World J Urol 2009;27:295–300
4 Bladder Cancer. American Cancer Society.
https://www.cancer.org/cancer/bladder-cancer.html
About
Hexvix®/Cysview® (hexaminolevulinate
HCl)
Hexvix/Cysview is a drug that preferentially accumulates in
cancer cells in the bladder, making them glow bright pink during
Blue Light Cystoscopy (BLC®). BLC with Hexvix/Cysview,
compared to standard white light cystoscopy alone, improves the
detection of tumors and leads to more complete resection, fewer
residual tumors, and better management decisions.
Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all other
markets. Photocure is commercializing Cysview/Hexvix directly in
the U.S. and Europe and has
strategic partnerships for the commercialization of Hexvix/Cysview
in China, Chile, Australia, New
Zealand and Israel. Please
refer to https://photocure.com/partners/our-partners for
further information on our commercial partners.
About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative
solutions to improve the lives of bladder cancer patients. Our
unique technology, making cancer cells glow bright pink, has led to
better health outcomes for patients worldwide. Photocure is
headquartered in Oslo, Norway, and
listed on the Oslo Stock Exchange (OSE: PHO). For more information,
please visit us at www.photocure.com, www.hexvix.com,
www.cysview.com
For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com
David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com
Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no
The following files are available for download:
|
https://mb.cision.com/Main/17498/3717570/1857901.pdf
|
Release
|
View original
content:https://www.prnewswire.com/news-releases/clinical-data-presented-at-asco-gu-demonstrates-reduced-risk-of-recurrence-in-non-muscle-invasive-bladder-cancer-with-the-use-of-blc-301750526.html
SOURCE Photocure